ArriVent BioPharma (AVBP) Gains from Investment Securities (2023 - 2026)

ArriVent BioPharma has disclosed Gains from Investment Securities across 4 years of filings, most recently posting $7.2 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $7.2 million, up 77.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.2 million (up 77.88% YoY), and the FY2025 annual result was $4.3 million, up 71.02% from the prior year.
• Gains from Investment Securities came in at $7.2 million for Q1 2026 at ArriVent BioPharma, up from $4.3 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $7.2 million in Q1 2026 to a low of $801091.0 in Q4 2023.
• The 4-year median for Gains from Investment Securities is $2.3 million (2024), against an average of $2.9 million.
• Across the five-year window, Gains from Investment Securities soared 215.96% in 2024 and gained 3.05% in 2025, its largest moves.
• ArriVent BioPharma's Gains from Investment Securities stood at $801091.0 in 2023, then jumped by 215.96% to $2.5 million in 2024, then surged by 71.02% to $4.3 million in 2025, then soared by 66.8% to $7.2 million in 2026.
• The last three Gains from Investment Securities figures came in at $7.2 million (Q1 2026), $4.3 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.